Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection

Liu, Chen–Hua; Lin, Jou‐Wei; Liu, Chun‐Jen; Su, Tung‐Hung; Wu, Jo‐Hsuan; Tseng, Tai‐Chung; Chen, Pei‐Jer; Kao, Jia‐Horng

doi:10.1016/j.cgh.2022.01.050

Cited by 10 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Liu CH et al conducted a prospective cohort study among 1987 patients with eGFR ≥15 mL/min/1.73 m 2 receiving interferon or DAA treatment. They also recommended that the kidney function and risk of ESRD were significantly improved in patients who completed sustained virologic response with anti-HCV therapy [ 39 ]. In summary, CKD has an unavoidably progressive natural course, and studies that fail to prove a favorable effect in the post-treatment period should be interpreted by comparing them with studies that analyzed eGFR slopes before and after DAA treatment.…”

Section: Discussionmentioning

confidence: 99%

“…In summary, CKD has an unavoidably progressive natural course, and studies that fail to prove a favorable effect in the post-treatment period should be interpreted by comparing them with studies that analyzed eGFR slopes before and after DAA treatment. The results of these studies recommend the benefits of DAA treatment in slowing down the renal function decline [ 37 , 38 , 39 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

From Bench to Bedside: Clinical and Biomedical Investigations on Hepatitis C Virus (HCV) Genotypes and Risk Factors for Albuminuria

Hsiao

Tsai

et al. 2022

Bioengineering

View full text Add to dashboard Cite

An extrahepatic manifestation of nephropathies can be a feature of the chronic hepatitis C virus (HCV) infection. Albuminuria is a major risk factor for nephropathies and chronic kidney disease (CKD). The correlation between HCV genotypes and albuminuria is still unclear. In this study, investigations have been done for the biomedical tools and methodologies used in the National Health and Nutrition Examination Survey (NHANES) public database. We searched the 2007–2016 NHANES public database to retrieve data regarding the different HCV genotypes and clinical scenarios. This study attempted to investigate the impacts of HCV genetic diversity, associated comorbidities, and racial differences on albuminuria. The urine albumin/creatinine ratio (ACR) was the primary endpoint. Among 40,856 participants, 336 participants with positive and 237 with negative HCV RNA tests were analyzed, excluding 14,454 participants with negative HCV antibodies and 25,828 which were missed. After controlling for sex, race, education level, smoking, diabetes mellitus, hepatitis B, alcohol use, and body mass index (BMI) with a generalized linear equation, HCV genotype 2 was more likely than any other genotype to cause albuminuria based on the urine ACR (p < 0.001). The generalized linear equation also demonstrated a significantly higher urine ACR, including hepatitis B (p < 0.001), diabetes mellitus (p < 0.001), and smoking (p = 0.026). In summary, the patients with HCV genotype 2 presented with increased albuminuria in comparison with other HCV genotypes in this 10-year retrospective analysis. HCV infection could be a risk factor of CKD; early diagnosis and appropriate treatment may improve clinical outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

From Bench to Bedside: Clinical and Biomedical Investigations on Hepatitis C Virus (HCV) Genotypes and Risk Factors for Albuminuria

Hsiao

Tsai

et al. 2022

Bioengineering

View full text Add to dashboard Cite

show abstract

“…In addition, all participants underwent laboratory testing for hemogram, international normalized ratio (INR), serum albumin, total bilirubin (upper limit of normal [ULN]: 1.0 mg/dL), direct bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) (ULN: 30 U/L for males and 19 U/L for females), estimated glomerular ltration rate (eGFR) as calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, anti-HCV, hepatitis B surface antigen (HBsAg) (Abbott Architect HBsAg qualitative assay, Abbott Laboratories, Abbott Park, Illinois, USA) to con rm hepatitis B virus (HBV) coinfection, anti-HIV (Abbott Architect HIV Ag/Ab Combo, Abbott Laboratories, Abbott Park, Illinois, USA), HCV RNA, HCV genotype (Roche Cobas HCV GT, Roche Diagnostics GmbH, Mannheim, Germany, or Abbott RealTime HCV Genotype II, Abbott Laboratories, Abbott Park, Illinois, USA) to con rm HIV coinfection. [32][33][34] The severity of hepatic brosis was graded by brosis index based on four parameters (FIB-4) with the cut-off values of < 1.45, 1.45-3.25, and > 3.25. 35 Hepatic imaging studies, including ultrasonography, computed tomography or magnetic resonance imaging, were performed before treatment to detect active HCC or decompensated cirrhosis.…”

Section: Methodsmentioning

confidence: 99%

Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

et al. 2023

Self Cite

View full text Add to dashboard Cite

BackgroundReal-world data are scarce about the effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) for retreating East Asian patients with hepatitis C virus (HCV) infection who previously received NS5A direct-acting antivirals (DAAs). We conducted a multicenter study to assess the performance of SOF/VEL/VOX in patients who were not responsive to prior NS5A inhibitors in Taiwan. MethodsBetween September 2021 and May 2022, 107 patients who failed NS5A inhibitor-containing DAAs with SOF/VEL/VOX salvage therapy for 12 weeks were included at 16 academic centers. The sustained virologic response at off-treatment week 12 (SVR 12 ) was assessed in the evaluable (EP) and per-protocol (PP) populations. The safety pro les were also reported. ResultsAll patients completed 12 weeks of treatment and achieved an end-of-treatment virologic response. The SVR 12 rates were 97.2% (95% con dence interval (CI): 92.1%-99.0%) and 100% (95% CI: 96.4%-100%) in EP and PP populations. Three (2.8%) patients were lost to off-treatment follow-up and did not meet SVR 12 in the EP population. No baseline factors predicted SVR 12 . Two (1.9%) not-fatal serious adverse events (AE) occurred, but unrelated to SOF/VEL/VOX. Sixteen (15.0%) had grade 2 total bilirubin elevation, and three (2.8%) had grade 2 alanine transaminase (ALT) elevation. Thirteen (81.3%) of the 16 patients with grade 2 total bilirubin elevation had unconjugated hyperbilirubinemia. The estimated glomerular ltration rates (eGFR) were comparable between baseline and SVR 12 , regardless of baseline renal reserve. ConclusionsSOF/VEL/VOX is highly e cacious and well-tolerated for East Asian HCV patients previously treated with NS5A inhibitor-containing DAAs.

show abstract

“…The upper limit of normal (ULN) of ALT level was 30 U/L for men and 19 U/L for women [ 38 ]. The eGFR and the CKD stage were calculated and graded via chronic kidney disease-epidemiology collaboration (CKD-EPI) equation [ 39 , 40 ]. Metabolic-dysfunction-associated fatty liver disease (MAFLD) was defined by the international expert consensus statement, including three different phenotypes (overweight or obesity; lean/normal weight; type 2 DM) [ 41 ].…”

Section: Methodsmentioning

confidence: 99%

Serum Mac-2 Binding Protein Glycosylation Isomer to Predict the Severity of Hepatic Fibrosis in Patients with Hepatitis C Virus Infection

Liu

et al. 2022

Diagnostics

View full text Add to dashboard Cite

Large-scale studies to assess the utility of the Mac-2 binding protein glycosylation isomer (M2BPGi) in predicting hepatic fibrosis in patients with hepatitis C virus (HCV) infection are limited. Serum M2BPGi level determination was performed in 1460 patients with HCV who received liver stiffness measurement (LSM) using transient elastography (TE). The correlation of LSM and grade of hepatic fibrosis as staged by TE with M2BPGi was assessed. Receiver operating characteristic (ROC) curves were constructed to evaluate the diagnostic power of M2BPGi for fibrosis stages of ≥F2, ≥F3, and F4. The selected M2BPGi cutoff values were chosen based on the maximal Youden index, a positive likelihood ratio (LR) ≥ 10, and a negative LR ≤ 0.1. Serum M2BPGi level was highly correlated with LSM (Pearson correlation coefficient: 0.567, p < 0.001) and hepatic fibrosis stage (Spearman’s rank correlation coefficient: 0.772, p < 0.001). The areas under ROC curves (AUROCs) of M2BPGi for ≥F2, ≥F3, and F4 were 0.865 (95% confidence interval [CI]: 0.846–0.884), 0.937 (95 % CI: 0.922–0.952), and 0.962 (95% CI: 0.951–0.972). The maximal Youden indices for ≥F2, ≥F3, and F4 were 1.72, 2.65, and 3.93. By selecting M2BPGi cutoff values with a positive LR ≥ 10 and a negative LR ≤ 0.1, clinicians were able to correctly discriminate F2, F3, and F4 in 69.1%, 77.8%, and 90.1% of patients. In conclusion, serum M2BPGi is a good diagnostic tool to predict the severity of hepatic fibrosis in patients with HCV infection.

show abstract

Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection

Cited by 10 publications

References 33 publications

From Bench to Bedside: Clinical and Biomedical Investigations on Hepatitis C Virus (HCV) Genotypes and Risk Factors for Albuminuria

From Bench to Bedside: Clinical and Biomedical Investigations on Hepatitis C Virus (HCV) Genotypes and Risk Factors for Albuminuria

Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Serum Mac-2 Binding Protein Glycosylation Isomer to Predict the Severity of Hepatic Fibrosis in Patients with Hepatitis C Virus Infection

Contact Info

Product

Resources

About